Endoscopic submucosal dissection (ESD) represents a significant advance in therapeutic endoscopy with the major advantage being the ability to achieve a higher en bloc resection rate for early stage ...
Background and Aims: To clarify optimal therapeutic strategies for early gastric cancers without vestigial remnant or recurrence, we evaluated the benefits of endoscopic mucosal resection (EMR) and ...
Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Endoscopic Submucosal Dissection Market - A Global and Regional Analysis: Focus on Indication, Product, End user, Country, and Region - Analysis and ...
Background Oncological principles favour en bloc R0 excision for curative endoscopic resection. In Barrett’s neoplasia, ...
Additionally, the publication of clinical guidelines by leading gastroenterological societies in Western countries has legitimized the use of ESD for treating early-stage gastric, esophageal, and ...
A research team at Tohoku University, in collaboration with Denka Company Limited and U-A Corporation, has developed a ...
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic CRC: Analysis of patients treated within the PanaMa trial (AIO KRK 0212). Panitumumab ...
Please provide your email address to receive an email when new articles are posted on . CHARLOTTE, N.C. — Same-day discharge is a safe and feasible option for patients who undergo endoscopic ...
A prospective clinical trial from researchers in Japan shows magnetic-anchor-guided endoscopic submucosal dissection for large early gastric cancer to be a feasible and safe method in humans.
Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback